I was reading through some articles this weekend, when I found one from BusinessWeek, questioning the viability of herbicide producer Monsanto Co. (NYSE: MON).

The article focuses on the past six months, a period when MON shares have lagged behind the broader market, and then wonders if the stock is still a viable long-term investment. The story was prompted by last Thursday's earnings forecast for $3.10 to $3.30 per share in fiscal 2010, which was well short of the $4.10 that the Street expects.

Continue reading When will Monsanto regain its Street-beating ways?

When will Monsanto regain its Street-beating ways? originally appeared on BloggingStocks on Mon, 14 Sep 2009 12:00:00 EST. Please see our terms for use of feeds.

"Genomics may be the 'next big thing' after the Internet and biotech. Finding those who can make money early onwill likely pay dividends to investors," expla]in small cap growth stock specialist Jim Oberweis, Jr.

In his The Oberweis Report, he explains the "politics" behind this bullish scenario as well as his top pick for log-term investors seeking exposure to the developing healthcare technologies if genomics and personalized medicine.

"We believe that the biotech boom was a direct consequence of rising National Health Institute (NIH) funding, cheap equity capital, and the ability to patent NIH-funded discoveries. And we see that happening again.

Continue reading Genomics: The next big thing?

Genomics: The next big thing? originally appeared on BloggingStocks on Mon, 18 May 2009 14:00:00 EST. Please see our terms for use of feeds.